Table of Contents Author Guidelines Submit a Manuscript
International Journal of Endocrinology
Volume 2018, Article ID 1349868, 12 pages
https://doi.org/10.1155/2018/1349868
Review Article

The Polycystic Ovary Syndrome and the Metabolic Syndrome: A Possible Chronobiotic-Cytoprotective Adjuvant Therapy

1Centre for Experimental and Applied Endocrinology (CENEXA, UNLP-CONICET-FCM), CEAS-CICPBA, La Plata Medical School, La Plata, Argentina
2BIOMED-UCA-CONICET and Department of Teaching and Research, Faculty of Medical Sciences, Pontificia Universidad Católica Argentina, Buenos Aires, Argentina

Correspondence should be addressed to Eduardo Spinedi; gro.axenec@idenips

Received 18 April 2018; Accepted 28 June 2018; Published 25 July 2018

Academic Editor: Maria C. Meriggiola

Copyright © 2018 Eduardo Spinedi and Daniel P. Cardinali. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group, “Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome,” Fertility and Sterility, vol. 81, no. 1, pp. 19–25, 2004. View at Publisher · View at Google Scholar · View at Scopus
  2. R. Azziz, E. Carmina, D. Dewailly et al., “The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report,” Fertility and Sterility, vol. 91, no. 2, pp. 456–488, 2009. View at Publisher · View at Google Scholar · View at Scopus
  3. L. J. Moran, R. Pasquali, H. J. Teede, K. M. Hoeger, and R. J. Norman, “Treatment of obesity in polycystic ovary syndrome: a position statement of the Androgen Excess and Polycystic Ovary Syndrome Society,” Fertility and Sterility, vol. 92, no. 6, pp. 1966–1982, 2009. View at Publisher · View at Google Scholar · View at Scopus
  4. B. O. Yildiz, R. Azziz, and Androgen Excess and PCOS Society, “Ovarian and adipose tissue dysfunction in polycystic ovary syndrome: report of the 4th special scientific meeting of the Androgen Excess and PCOS Society,” Fertility and Sterility, vol. 94, no. 2, pp. 690–693, 2010. View at Publisher · View at Google Scholar · View at Scopus
  5. R. Azziz, “Diagnostic criteria for polycystic ovary syndrome: a reappraisal,” Fertility and Sterility, vol. 83, no. 5, pp. 1343–1346, 2005. View at Publisher · View at Google Scholar · View at Scopus
  6. G. Garruti, R. Depalo, M. G. Vita et al., “Adipose tissue, metabolic syndrome and polycystic ovary syndrome: from pathophysiology to treatment,” Reproductive Biomedicine Online, vol. 19, no. 4, pp. 552–563, 2009. View at Publisher · View at Google Scholar · View at Scopus
  7. P. Fenichel, C. Rougier, S. Hieronimus, and N. Chevalier, “Which origin for polycystic ovaries syndrome: genetic, environmental or both?” Annales d'endocrinologie, vol. 78, no. 3, pp. 176–185, 2017. View at Publisher · View at Google Scholar · View at Scopus
  8. I. R. Ilie and C. E. Georgescu, “Polycystic ovary syndrome-epigenetic mechanisms and aberrant microRNA,” Advances in Clinical Chemistry, vol. 71, pp. 25–45, 2015. View at Publisher · View at Google Scholar · View at Scopus
  9. S. Behboudi-Gandevani, F. Ramezani Tehrani, M. Rostami Dovom et al., “Insulin resistance in obesity and polycystic ovary syndrome: systematic review and meta-analysis of observational studies,” Gynecological Endocrinology, vol. 32, no. 5, pp. 343–353, 2016. View at Publisher · View at Google Scholar · View at Scopus
  10. S. S. Lim, M. J. Davies, R. J. Norman, and L. J. Moran, “Overweight, obesity and central obesity in women with polycystic ovary syndrome: a systematic review and meta-analysis,” Human Reproduction Update, vol. 18, no. 6, pp. 618–637, 2012. View at Publisher · View at Google Scholar · View at Scopus
  11. P. L. Huang, “A comprehensive definition for metabolic syndrome,” Disease Models & Mechanisms, vol. 2, no. 5-6, pp. 231–237, 2009. View at Publisher · View at Google Scholar · View at Scopus
  12. L. Moran and H. Teede, “Metabolic features of the reproductive phenotypes of polycystic ovary syndrome,” Human Reproduction Update, vol. 15, no. 4, pp. 477–488, 2009. View at Publisher · View at Google Scholar · View at Scopus
  13. L. J. Moran, M. L. Misso, R. A. Wild, and R. J. Norman, “Impaired glucose tolerance, type 2 diabetes and metabolic syndrome in polycystic ovary syndrome: a systematic review and meta-analysis,” Human Reproduction Update, vol. 16, no. 4, pp. 347–363, 2010. View at Publisher · View at Google Scholar · View at Scopus
  14. L. J. Moran, W. A. March, M. J. Whitrow, L. C. Giles, M. J. Davies, and V. M. Moore, “Sleep disturbances in a community-based sample of women with polycystic ovary syndrome,” Human Reproduction, vol. 30, no. 2, pp. 466–472, 2015. View at Publisher · View at Google Scholar · View at Scopus
  15. B. Chatterjee, J. Suri, J. C. Suri, P. Mittal, and T. Adhikari, “Impact of sleep-disordered breathing on metabolic dysfunctions in patients with polycystic ovary syndrome,” Sleep Medicine, vol. 15, no. 12, pp. 1547–1553, 2014. View at Publisher · View at Google Scholar · View at Scopus
  16. H. Kahal, I. Kyrou, A. A. Tahrani, and H. S. Randeva, “Obstructive sleep apnoea and polycystic ovary syndrome: a comprehensive review of clinical interactions and underlying pathophysiology,” Clinical Endocrinology, vol. 87, no. 4, pp. 313–319, 2017. View at Publisher · View at Google Scholar · View at Scopus
  17. K. Nandalike, C. Agarwal, T. Strauss et al., “Sleep and cardiometabolic function in obese adolescent girls with polycystic ovary syndrome,” Sleep Medicine, vol. 13, no. 10, pp. 1307–1312, 2012. View at Publisher · View at Google Scholar · View at Scopus
  18. M. Barnaś, M. Maskey-Warzęchowska, P. Bielicki, M. Kumor, and R. Chazan, “Diurnal and nocturnal serum melatonin concentrations after treatment with continuous positive airway pressure in patients with obstructive sleep apnea,” Polish Archives of Internal Medicine, vol. 127, no. 9, pp. 589–596, 2017. View at Publisher · View at Google Scholar · View at Scopus
  19. A. J. R. Lim, Z. Huang, S. E. Chua, M. S. Kramer, and E. L. Yong, “Sleep duration, exercise, shift work and polycystic ovarian syndrome-related outcomes in a healthy population: a cross-sectional study,” PLoS One, vol. 11, no. 11, article e0167048, 2016. View at Publisher · View at Google Scholar · View at Scopus
  20. E. Spinedi, V. Mariani, M. Bulfon, M. Colombani-Vidal, and H. Scaglia, “Analysis of the hypothalamic-pituitary-ovary axis in the neonatally-androgenized female rat,” Journal of Endocrinological Investigation, vol. 13, no. 6, pp. 481–488, 1990. View at Publisher · View at Google Scholar · View at Scopus
  21. C. R. McCartney, “Maturation of sleep–wake gonadotrophin-releasing hormone secretion across puberty in girls: potential mechanisms and relevance to the pathogenesis of polycystic ovary syndrome,” Journal of Neuroendocrinology, vol. 22, no. 7, pp. 701–709, 2010. View at Publisher · View at Google Scholar · View at Scopus
  22. M. Ashwell, S. Chinn, S. Stalley, and J. S. Garrow, “Female fat distribution--a photographic and cellularity study,” International Journal of Obesity, vol. 2, no. 3, pp. 289–302, 1978. View at Google Scholar
  23. W. H. Mueller and S. K. Joos, “Android (centralized) obesity and somatotypes in men: association with mesomorphy,” Annals of Human Biology, vol. 12, no. 4, pp. 377–381, 1985. View at Publisher · View at Google Scholar · View at Scopus
  24. A. Basdevant, J. Raison, and B. Guy-Grand, “Influence of the distribution of body fat on vascular risk,” Presse Médicale, vol. 16, pp. 167–170, 1987. View at Google Scholar
  25. C. Alexanderson, E. Eriksson, E. Stener-Victorin et al., “Postnatal testosterone exposure results in insulin resistance, enlarged mesenteric adipocytes, and an atherogenic lipid profile in adult female rats: comparisons with estradiol and dihydrotestosterone,” Endocrinology, vol. 148, no. 11, pp. 5369–5576, 2007. View at Publisher · View at Google Scholar · View at Scopus
  26. M. Demissie, M. Lazic, E. M. Foecking, F. Aird, A. Dunaif, and J. E. Levine, “Transient prenatal androgen exposure produces metabolic syndrome in adult female rats,” American Journal of Physiology. Endocrinology and Metabolism, vol. 295, no. 2, pp. E262–E268, 2008. View at Publisher · View at Google Scholar · View at Scopus
  27. L. Mannerås-Holm, H. Leonhardt, J. Kullberg et al., “Adipose tissue has aberrant morphology and function in PCOS: enlarged adipocytes and low serum adiponectin, but not circulating sex steroids, are strongly associated with insulin resistance,” The Journal of Clinical Endocrinology and Metabolism, vol. 96, no. 2, pp. E304–E311, 2011. View at Publisher · View at Google Scholar · View at Scopus
  28. C. L. Su, M. Chen, P. N. Zhang, W. Xu, and J. F. Lin, “Effects and mechanism of testosterone on the production of inflammatory cytokines and glucose uptake in co-culture of RAW264.7 macrophage and 3T3-L1 adipocytes,” Zhonghua Yi Xue Za Zhi, vol. 96, no. 33, pp. 2665–2670, 2016. View at Google Scholar
  29. R. Singh, J. N. Artaza, W. E. Taylor et al., “Testosterone inhibits adipogenic differentiation in 3T3-L1 cells: nuclear translocation of androgen receptor complex with beta-catenin and T-cell factor 4 may bypass canonical Wnt signaling to down-regulate adipogenic transcription factors,” Endocrinology, vol. 147, no. 1, pp. 141–154, 2006. View at Publisher · View at Google Scholar · View at Scopus
  30. M. McIntosh, D. Hausman, R. Martin, and G. Hausman, “Dehydroepiandrosterone attenuates preadipocyte growth in primary cultures of stromal-vascular cells,” American Journal of Physiology-Endocrinology and Metabolism, vol. 275, no. 2, pp. E285–E293, 1998. View at Publisher · View at Google Scholar
  31. R. Singh, J. N. Artaza, W. E. Taylor, N. F. Gonzalez-Cadavid, and S. Bhasin, “Androgens stimulate myogenic differentiation and inhibit adipogenesis in C3H 10T1/2 pluripotent cells through an androgen receptor-mediated pathway,” Endocrinology, vol. 144, no. 11, pp. 5081–5088, 2003. View at Publisher · View at Google Scholar · View at Scopus
  32. J. Joyner, L. Hutley, and D. Cameron, “Intrinsic regional differences in androgen receptors and dihydrotestosterone metabolism in human preadipocytes,” Hormone and Metabolic Research, vol. 34, no. 5, pp. 223–228, 2002. View at Publisher · View at Google Scholar · View at Scopus
  33. M. G. Zubiría, J. Vidal-Bravo, E. Spinedi, and A. Giovambattista, “Relationship between impaired adipogenesis of retroperitoneal adipose tissue and hypertrophic obesity: role of endogenous glucocorticoid excess,” Journal of Cellular and Molecular Medicine, vol. 18, no. 8, pp. 1549–1561, 2014. View at Publisher · View at Google Scholar · View at Scopus
  34. A. Alzamendi, D. Castrogiovanni, H. H. Ortega, R. C. Gaillard, A. Giovambattista, and E. Spinedi, “Parametrial adipose tissue and metabolic dysfunctions induced by fructose-rich diet in normal and neonatal-androgenized adult female rats,” Obesity, vol. 18, no. 3, pp. 441–448, 2010. View at Publisher · View at Google Scholar · View at Scopus
  35. L. Ongaro, D. Castrogiovanni, A. Giovambattista, R. C. Gaillard, and E. Spinedi, “Enhanced proinflammatory cytokine response to bacterial lipopolysaccharide in the adult male rat after either neonatal or prepubertal ablation of biological testosterone activity,” Neuroimmunomodulation, vol. 18, no. 4, pp. 254–260, 2011. View at Publisher · View at Google Scholar · View at Scopus
  36. C. Pantoja, J. T. Huff, and K. R. Yamamoto, “Glucocorticoid signaling defines a novel commitment state during adipogenesis in vitro,” Molecular Biology of the Cell, vol. 19, no. 10, pp. 4032–4041, 2008. View at Publisher · View at Google Scholar · View at Scopus
  37. L. Ongaro, A. Giovambattista, and E. Spinedi, “Impact of neonatal manipulation of androgen receptor function on endocrine-metabolic programming in the juvenile female rat,” ISRN Endocrinology, vol. 2013, Article ID 181950, 7 pages, 2013. View at Publisher · View at Google Scholar
  38. M. N. Dieudonne, R. Pecquery, A. Boumediene, M. C. Leneveu, and Y. Giudicelli, “Androgen receptors in human preadipocytes and adipocytes: regional specificities and regulation by sex steroids,” American Journal of Physiology-Cell Physiology, vol. 274, no. 6, pp. C1645–C1652, 1998. View at Publisher · View at Google Scholar
  39. D. Macut, I. Božić-Antić, J. Bjekić-Macut, and K. Tziomalos, “Management of endocrine disease: polycystic ovary syndrome and nonalcoholic fatty liver disease,” European Journal of Endocrinology, vol. 177, no. 3, pp. R145–R158, 2017. View at Publisher · View at Google Scholar · View at Scopus
  40. W. S. Dantas, I. H. Murai, L. A. Perandini et al., “Acute exercise elicits differential expression of insulin resistance genes in the skeletal muscle of patients with polycystic ovary syndrome,” Clinical Endocrinology, vol. 86, no. 5, pp. 688–697, 2017. View at Publisher · View at Google Scholar · View at Scopus
  41. D. Macut, J. Bjekić-Macut, D. Rahelić, and M. Doknić, “Insulin and the polycystic ovary syndrome,” Diabetes Research and Clinical Practice, vol. 130, pp. 163–170, 2017. View at Publisher · View at Google Scholar · View at Scopus
  42. C. Bañuls, S. Rovira-Llopis, A. Martinez de Marañon et al., “Metabolic syndrome enhances endoplasmic reticulum, oxidative stress and leukocyte-endothelium interactions in PCOS,” Metabolism, vol. 71, pp. 153–162, 2017. View at Publisher · View at Google Scholar · View at Scopus
  43. C. Moretti, G. Lanzolla, M. Moretti, L. Gnessi, and E. Carmina, “Androgens and hypertension in men and women: a unifying view,” Current Hypertension Reports, vol. 19, no. 5, p. 44, 2017. View at Publisher · View at Google Scholar · View at Scopus
  44. S. Rodriguez-Cuenca, M. Monjo, A. M. Proenza, and P. Roca, “Depot differences in steroid receptor expression in adipose tissue: possible role of the local steroid milieu,” American Journal of Physiology. Endocrinology and Metabolism, vol. 288, no. 1, pp. E200–E207, 2005. View at Publisher · View at Google Scholar · View at Scopus
  45. L. Ongaro, N. R. Salvetti, A. Giovambattista, E. Spinedi, and H. H. Ortega, “Neonatal androgenization-induced early endocrine-metabolic and ovary misprogramming in the female rat,” Life Sciences, vol. 130, pp. 66–72, 2015. View at Publisher · View at Google Scholar · View at Scopus
  46. C. J. Smith and K. K. Ryckman, “Epigenetic and developmental influences on the risk of obesity, diabetes, and metabolic syndrome,” Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, vol. 8, pp. 295–302, 2015. View at Publisher · View at Google Scholar · View at Scopus
  47. S. O'Neill and L. O'Driscoll, “Metabolic syndrome: a closer look at the growing epidemic and its associated pathologies,” Obesity Reviews, vol. 16, no. 1, pp. 1–12, 2015. View at Publisher · View at Google Scholar · View at Scopus
  48. A. Kalsbeek, S. la Fleur, and E. Fliers, “Circadian control of glucose metabolism,” Molecular Metabolism, vol. 3, no. 4, pp. 372–383, 2014. View at Publisher · View at Google Scholar · View at Scopus
  49. W. Huang, K. M. Ramsey, B. Marcheva, and J. Bass, “Circadian rhythms, sleep, and metabolism,” The Journal of Clinical Investigation, vol. 121, no. 6, pp. 2133–2141, 2011. View at Publisher · View at Google Scholar · View at Scopus
  50. R. Karthikeyan, G. Marimuthu, D. W. Spence et al., “Should we listen to our clock to prevent type 2 diabetes mellitus?” Diabetes Research and Clinical Practice, vol. 106, no. 2, pp. 182–190, 2014. View at Publisher · View at Google Scholar · View at Scopus
  51. E. McFadden, M. E. Jones, M. J. Schoemaker, A. Ashworth, and A. J. Swerdlow, “The relationship between obesity and exposure to light at night: cross-sectional analyses of over 100,000 women in the Breakthrough Generations Study,” American Journal of Epidemiology, vol. 180, no. 3, pp. 245–250, 2014. View at Publisher · View at Google Scholar · View at Scopus
  52. H. E. Molzof, M. D. Wirth, J. B. Burch et al., “The impact of meal timing on cardiometabolic syndrome indicators in shift workers,” Chronobiology International, vol. 34, no. 3, pp. 337–348, 2017. View at Publisher · View at Google Scholar · View at Scopus
  53. Y. C. Lin, I. C. Hsieh, and P. C. Chen, “Utilizing the metabolic syndrome component count in workers’ health surveillance: an example of day-time vs. day-night rotating shift workers,” International Journal of Occupational Medicine and Environmental Health, vol. 28, no. 4, pp. 675–688, 2015. View at Publisher · View at Google Scholar · View at Scopus
  54. Y. Kawabe, Y. Nakamura, S. Kikuchi et al., “Relationship between shift work and clustering of the metabolic syndrome diagnostic components,” Journal of Atherosclerosis and Thrombosis, vol. 21, no. 7, pp. 703–711, 2014. View at Publisher · View at Google Scholar · View at Scopus
  55. T. Arora, M. Z. Chen, A. R. Cooper, R. C. Andrews, and S. Taheri, “The impact of sleep debt on excess adiposity and insulin sensitivity in patients with early type 2 diabetes mellitus,” Journal of Clinical Sleep Medicine, vol. 12, no. 5, pp. 673–680, 2016. View at Publisher · View at Google Scholar · View at Scopus
  56. D. P. Cardinali, P. Cano, V. Jimenez-Ortega, and A. I. Esquifino, “Melatonin and the metabolic syndrome: physiopathologic and therapeutical implications,” Neuroendocrinology, vol. 93, no. 3, pp. 133–142, 2011. View at Publisher · View at Google Scholar · View at Scopus
  57. D. P. Cardinali and R. Hardeland, “Inflammaging, metabolic syndrome and melatonin: a call for treatment studies,” Neuroendocrinology, vol. 104, no. 4, pp. 382–397, 2017. View at Publisher · View at Google Scholar · View at Scopus
  58. D. P. Cardinali and D. E. Vigo, “Melatonin, mitochondria and the metabolic syndrome,” Cellular and Molecular Life Sciences, vol. 74, no. 21, pp. 3941–3954, 2017. View at Publisher · View at Google Scholar · View at Scopus
  59. H. Tamura, A. Takasaki, T. Taketani et al., “The role of melatonin as an antioxidant in the follicle,” Journal of Ovarian Research, vol. 5, no. 1, p. 5, 2012. View at Publisher · View at Google Scholar
  60. H. Tamura, Y. Nakamura, A. Korkmaz et al., “Melatonin and the ovary: physiological and pathophysiological implications,” Fertility and Sterility, vol. 92, no. 1, pp. 328–343, 2009. View at Publisher · View at Google Scholar · View at Scopus
  61. R. J. Reiter, H. Tamura, D. X. Tan, and X. Y. Xu, “Melatonin and the circadian system: contributions to successful female reproduction,” Fertility and Sterility, vol. 102, no. 2, pp. 321–328, 2014. View at Publisher · View at Google Scholar · View at Scopus
  62. M. Pan, Y. L. Song, J. M. Xu, and H. Z. Gan, “Melatonin ameliorates nonalcoholic fatty liver induced by high-fat diet in rats,” Journal of Pineal Research, vol. 41, no. 1, pp. 79–84, 2006. View at Publisher · View at Google Scholar · View at Scopus
  63. I. Stumpf, I. Bazwinsky, and E. Peschke, “Modulation of the cGMP signaling pathway by melatonin in pancreatic beta-cells,” Journal of Pineal Research, vol. 46, no. 2, pp. 140–147, 2009. View at Publisher · View at Google Scholar · View at Scopus
  64. R. Tarquini, V. Bruni, F. Perfetto, L. Bigozzi, L. Tapparini, and B. Tarquini, “Hypermelatoninemia in women with polycystic ovarian syndrome,” The European Journal of Contraception & Reproductive Health Care, vol. 1, no. 4, pp. 349-350, 1996. View at Google Scholar
  65. R. Luboshitzky, G. Qupti, A. Ishay, Z. Shen-Orr, B. Futerman, and S. Linn, “Increased 6-sulfatoxymelatonin excretion in women with polycystic ovary syndrome,” Fertility and Sterility, vol. 76, no. 3, pp. 506–510, 2001. View at Publisher · View at Google Scholar · View at Scopus
  66. R. Luboshitzky, P. Herer, and Z. Shen-Orr, “Urinary 6-sulfatoxymelatonin excretion in hyperandrogenic women: the effect of cyproterone acetate-ethinyl estradiol treatment,” Experimental and Clinical Endocrinology & Diabetes, vol. 112, no. 2, pp. 102–107, 2004. View at Publisher · View at Google Scholar · View at Scopus
  67. D. D. Terzieva, M. M. Orbetzova, M. D. Mitkov, and N. G. Mateva, “Serum melatonin in women with polycystic ovary syndrome,” Folia Medica, vol. 55, no. 2, pp. 10–15, 2013. View at Publisher · View at Google Scholar
  68. M. Jain, S. Jain, T. B. Singh, C. Haldar, and P. Jain, “Melatonin and its correlation with testosterone in polycystic ovarian syndrome,” Journal of Human Reproductive Sciences, vol. 6, no. 4, pp. 253–258, 2013. View at Publisher · View at Google Scholar
  69. M. L. Dubocovich, P. Delagrange, D. N. Krause, D. Sugden, D. P. Cardinali, and J. Olcese, “International Union of Basic and Clinical Pharmacology. LXXV. Nomenclature, classification, and pharmacology of G protein-coupled melatonin receptors,” Pharmacological Reviews, vol. 62, no. 3, pp. 343–380, 2010. View at Publisher · View at Google Scholar · View at Scopus
  70. I. Prokopenko, C. Langenberg, J. C. Florez et al., “Variants in MTNR1B influence fasting glucose levels,” Nature Genetics, vol. 41, no. 1, pp. 77–81, 2009. View at Publisher · View at Google Scholar · View at Scopus
  71. M. A. Matuszek, A. Anton, S. Thillainathan, and N. J. Armstrong, “Increased insulin following an oral glucose load, genetic variation near the melatonin receptor MTNR1B, but no biochemical evidence of endothelial dysfunction in young Asian men and women,” PLoS One, vol. 10, no. 7, article e0133611, 2015. View at Publisher · View at Google Scholar · View at Scopus
  72. Y. Zhan, C. Li, Q. Gao, J. Chen, S. Yu, and S. G. Liu, “Association between the rs4753426 polymorphism in MTNR1B with fasting plasma glucose level and pancreatic β-cell function in gestational diabetes mellitus,” Genetics and Molecular Research, vol. 14, no. 3, pp. 8778–8785, 2015. View at Publisher · View at Google Scholar · View at Scopus
  73. M. Tarnowski, D. Malinowski, K. Safranow, V. Dziedziejko, and A. Pawlik, “MTNR1A and MTNR1B gene polymorphisms in women with gestational diabetes,” Gynecological Endocrinology, vol. 33, no. 5, pp. 395–398, 2017. View at Publisher · View at Google Scholar · View at Scopus
  74. J. Dupuis, DIAGRAM Consortium, C. Langenberg et al., “New genetic loci implicated in fasting glucose homeostasis and their impact on type 2 diabetes risk,” Nature Genetics, vol. 42, no. 2, pp. 105–116, 2010. View at Publisher · View at Google Scholar · View at Scopus
  75. S. Liao, Y. Liu, Y. Tan et al., “Association of genetic variants of melatonin receptor 1B with gestational plasma glucose level and risk of glucose intolerance in pregnant Chinese women,” PLoS One, vol. 7, no. 7, article e40113, 2012. View at Publisher · View at Google Scholar · View at Scopus
  76. C. Liu, Y. Wu, H. Li et al., “MTNR1B rs10830963 is associated with fasting plasma glucose, HbA1C and impaired beta-cell function in Chinese Hans from Shanghai,” BMC Medical Genetics, vol. 11, p. 59, 2010. View at Publisher · View at Google Scholar · View at Scopus
  77. X. Song, X. Sun, G. Ma et al., “Family association study between melatonin receptor gene polymorphisms and polycystic ovary syndrome in Han Chinese,” European Journal of Obstetrics, Gynecology, and Reproductive Biology, vol. 195, pp. 108–112, 2015. View at Publisher · View at Google Scholar · View at Scopus
  78. L. Wang, Y. Wang, X. Zhang et al., “Common genetic variation in MTNR1B is associated with serum testosterone, glucose tolerance, and insulin secretion in polycystic ovary syndrome patients,” Fertility and Sterility, vol. 94, no. 6, pp. 2486–2489.e2, 2010. View at Publisher · View at Google Scholar · View at Scopus
  79. C. Li, Y. Shi, L. You, L. Wang, and Z. J. Chen, “Association of rs10830963 and rs10830962 SNPs in the melatonin receptor (MTNR1B) gene among Han Chinese women with polycystic ovary syndrome,” Molecular Human Reproduction, vol. 17, no. 3, pp. 193–198, 2011. View at Publisher · View at Google Scholar · View at Scopus
  80. C. Li, Y. Shi, L. You, L. Wang, and Z. J. Chen, “Melatonin receptor 1A gene polymorphism associated with polycystic ovary syndrome,” Gynecologic and Obstetric Investigation, vol. 72, no. 2, pp. 130–134, 2011. View at Publisher · View at Google Scholar · View at Scopus
  81. M. K. Kim, E. A. Park, H. J. Kim et al., “Does supplementation of in-vitro culture medium with melatonin improve IVF outcome in PCOS?” Reproductive Biomedicine Online, vol. 26, no. 1, pp. 22–29, 2013. View at Publisher · View at Google Scholar · View at Scopus
  82. A. Pacchiarotti, G. Carlomagno, G. Antonini, and A. Pacchiarotti, “Effect of myo-inositol and melatonin versus myo-inositol, in a randomized controlled trial, for improving in vitro fertilization of patients with polycystic ovarian syndrome,” Gynecological Endocrinology, vol. 32, no. 1, pp. 69–73, 2016. View at Publisher · View at Google Scholar · View at Scopus
  83. V. Tagliaferri, D. Romualdi, and E. Scarinci, “Melatonin treatment may be able to restore menstrual cyclicity in women with PCOS: a pilot study,” Reproductive Sciences, vol. 25, no. 2, pp. 269–275, 2017. View at Publisher · View at Google Scholar · View at Scopus
  84. S. Stanosz, J. von Mach-Szczypinski, K. Sieja, and J. Kooeciuszkiewicz, “Micronized estradiol and progesterone therapy in primary, preinvasive endometrial cancer (1A/G1) in young women with polycystic ovarian syndrome,” The Journal of Clinical Endocrinology and Metabolism, vol. 99, no. 12, pp. E2472–E2476, 2014. View at Publisher · View at Google Scholar · View at Scopus
  85. N. Mesri Alamdari, R. Mahdavi, N. Roshanravan, N. Lotfi Yaghin, A. Ostadrahimi, and E. Faramarzi, “A double-blind, placebo-controlled trial related to the effects of melatonin on oxidative stress and inflammatory parameters of obese women,” Hormone and Metabolic Research, vol. 47, no. 7, pp. 504–508, 2015. View at Publisher · View at Google Scholar · View at Scopus
  86. A. K. Amstrup, T. Sikjaer, S. B. Pedersen, L. Heickendorff, L. Mosekilde, and L. Rejnmark, “Reduced fat mass and increased lean mass in response to 1 year of melatonin treatment in postmenopausal women: a randomized placebo-controlled trial,” Clinical Endocrinology, vol. 84, no. 3, pp. 342–347, 2016. View at Publisher · View at Google Scholar · View at Scopus
  87. M. Kozirog, A. R. Poliwczak, P. Duchnowicz, M. Koter-Michalak, J. Sikora, and M. Broncel, “Melatonin treatment improves blood pressure, lipid profile, and parameters of oxidative stress in patients with metabolic syndrome,” Journal of Pineal Research, vol. 50, no. 3, pp. 261–266, 2011. View at Publisher · View at Google Scholar · View at Scopus
  88. A. Goyal, P. D. Terry, H. M. Superak et al., “Melatonin supplementation to treat the metabolic syndrome: a randomized controlled trial,” Diabetology and Metabolic Syndrome, vol. 6, no. 1, p. 124, 2014. View at Publisher · View at Google Scholar · View at Scopus
  89. F. Romo-Nava, D. Alvarez-Icaza González, A. Fresán-Orellana et al., “Melatonin attenuates antipsychotic metabolic effects: an eight-week randomized, double-blind, parallel-group, placebo-controlled clinical trial,” Bipolar Disorders, vol. 16, no. 4, pp. 410–421, 2014. View at Publisher · View at Google Scholar · View at Scopus
  90. A. Modabbernia, P. Heidari, R. Soleimani et al., “Melatonin for prevention of metabolic side-effects of olanzapine in patients with first-episode schizophrenia: randomized double-blind placebo-controlled study,” Journal of Psychiatric Research, vol. 53, pp. 133–140, 2014. View at Publisher · View at Google Scholar · View at Scopus
  91. A. Mostafavi, M. Solhi, M. R. Mohammadi, M. Hamedi, M. Keshavarzi, and S. Akhondzadeh, “Melatonin decreases olanzapine induced metabolic side-effects in adolescents with bipolar disorder: a randomized double-blind placebo-controlled trial,” Acta Medica Iranica, vol. 52, no. 10, pp. 734–739, 2014. View at Google Scholar
  92. V. B. Shatilo, E. V. Bondarenko, and I. A. Antoniuk-Shcheglova, “Pineal gland melatonin-producing function in elderly patients with hypertensive disease: age peculiarities,” Advances in Gerontology, vol. 23, no. 4, pp. 539–542, 2010. View at Google Scholar
  93. M. Gonciarz, Z. Gonciarz, W. Bielanski et al., “The effects of long-term melatonin treatment on plasma liver enzymes levels and plasma concentrations of lipids and melatonin in patients with nonalcoholic steatohepatitis: a pilot study,” Journal of Physiology and Pharmacology, vol. 63, no. 1, pp. 35–40, 2012. View at Google Scholar
  94. M. Gonciarz, Z. Gonciarz, W. Bielanski et al., “The pilot study of 3-month course of melatonin treatment of patients with nonalcoholic steatohepatitis: effect on plasma levels of liver enzymes, lipids and melatonin,” Journal of Physiology and Pharmacology, vol. 61, no. 6, pp. 705–710, 2010. View at Google Scholar
  95. S. A. Hussain, H. M. Khadim, B. H. Khalaf, S. H. Ismail, K. I. Hussein, and A. S. Sahib, “Effects of melatonin and zinc on glycemic control in type 2 diabetic patients poorly controlled with metformin,” Saudi Medical Journal, vol. 27, no. 10, pp. 1483–1488, 2006. View at Google Scholar
  96. C. J. McMullan, G. C. Curhan, E. S. Schernhammer, and J. P. Forman, “Association of nocturnal melatonin secretion with insulin resistance in nondiabetic young women,” American Journal of Epidemiology, vol. 178, no. 2, pp. 231–238, 2013. View at Publisher · View at Google Scholar · View at Scopus
  97. P. Rubio-Sastre, F. A. J. L. Scheer, P. Gómez-Abellán, J. A. Madrid, and M. Garaulet, “Acute melatonin administration in humans impairs glucose tolerance in both the morning and evening,” Sleep, vol. 37, no. 10, pp. 1715–1719, 2014. View at Publisher · View at Google Scholar · View at Scopus
  98. R. H. Eckel, C. M. Depner, L. Perreault et al., “Morning circadian misalignment during short sleep duration impacts insulin sensitivity,” Current Biology, vol. 25, no. 22, pp. 3004–3010, 2015. View at Publisher · View at Google Scholar · View at Scopus
  99. K. H. Rubin, D. Glintborg, M. Nybo, B. Abrahamsen, and M. Andersen, “Development and risk factors of type 2 diabetes in a nationwide population of women with polycystic ovary syndrome,” The Journal of Clinical Endocrinology and Metabolism, vol. 102, no. 10, pp. 3848–3857, 2017. View at Publisher · View at Google Scholar · View at Scopus
  100. H. Ahmadieh and S. Azar, “Effects of sodium glucose cotransporter-2 inhibitors on serum uric acid in type 2 diabetes mellitus,” Diabetes Technology & Therapeutics, vol. 19, no. 9, pp. 507–512, 2017. View at Publisher · View at Google Scholar
  101. K. N. Lew and A. Wick, “Pharmacotherapy of type 2 diabetes mellitus: navigating current and new therapies,” Medsurg Nursing, vol. 24, pp. 413–419, 2015. View at Google Scholar
  102. R. B. Goldberg, J. R. Guyton, T. Mazzone et al., “Relationships between metabolic syndrome and other baseline factors and the efficacy of ezetimibe/simvastatin and atorvastatin in patients with type 2 diabetes and hypercholesterolemia,” Diabetes Care, vol. 33, no. 5, pp. 1021–1024, 2010. View at Publisher · View at Google Scholar · View at Scopus
  103. M. A. Nauck and N. Friedrich, “Do GLP-1-based therapies increase cancer risk?” Diabetes Care, vol. 36, Supplement 2, pp. S245–S252, 2013. View at Publisher · View at Google Scholar · View at Scopus
  104. S. A. Pai and A. S. Majumdar, “Protective effects of melatonin against metabolic and reproductive disturbances in polycystic ovary syndrome in rats,” The Journal of Pharmacy and Pharmacology, vol. 66, no. 12, pp. 1710–1721, 2014. View at Publisher · View at Google Scholar · View at Scopus
  105. M. F. Prata Lima, E. C. Baracat, and M. J. Simoes, “Effects of melatonin on the ovarian response to pinealectomy or continuous light in female rats: similarity with polycystic ovary syndrome,” Brazilian Journal of Medical and Biological Research, vol. 37, no. 7, pp. 987–995, 2004. View at Publisher · View at Google Scholar · View at Scopus
  106. F. Nikmard, E. Hosseini, M. Bakhtiyari, M. Ashrafi, F. Amidi, and R. Aflatoonian, “Effects of melatonin on oocyte maturation in PCOS mouse model,” Animal Science Journal, vol. 88, no. 4, pp. 586–592, 2017. View at Publisher · View at Google Scholar · View at Scopus
  107. A. J. J. M. Lemos, C. A. Peixoto, Á. A. C. Teixeira et al., “Effect of the combination of metformin hydrochloride and melatonin on oxidative stress before and during pregnancy, and biochemical and histopathological analysis of the livers of rats after treatment for polycystic ovary syndrome,” Toxicology and Applied Pharmacology, vol. 280, no. 1, pp. 159–168, 2014. View at Publisher · View at Google Scholar · View at Scopus
  108. E. S. Pagano, E. Spinedi, and J. J. Gagliardino, “White adipose tissue and circadian rhythm dysfunctions in obesity: pathogenesis and available therapies,” Neuroendocrinology, vol. 104, no. 4, pp. 347–363, 2017. View at Publisher · View at Google Scholar · View at Scopus